Johnson & Johnson sees 'very viable path forward' for its COVID-19 vaccine despite safety, manufacturing setbacks

It’s going to be a big week for Johnson & Johnson’s COVID-19 vaccine, which has hit pitfall after pitfall since its launch. European officials offered renewed backing for the shot Tuesday—with a warning about its risks—and a key Centers for Disease Control and Prevention committee is set to meet Friday to review the latest data. By Saturday, depending on that committee's vote, the vaccine could have a clear road ahead in the U.S. Meanwhile, the company is trying to recover from a manufacturing snafu at its U.S. partner Emergent BioSolutions. But whatever happens right now, J&J execs say they are confident the company can get its launch back up to speed.